5-Amino-1MQ
NNMT inhibitor
5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) that has shown fat-reduction effects in mouse and cell studies, with essentially no published human evidence.
Regulatory status: Not an approved drug. It is a laboratory research compound with no FDA or other regulatory approval, and no peer-reviewed human clinical trial data were located.
Default vial
50 mg
Default mix
5 mL
Reported range
150 mcg–5 mg (injectable, sources vary widely); 50–150 mg (oral)
Draw (U-100)
5 u
Not a peptide — a small-molecule NNMT inhibitor, and the route it is actually used by is oral capsule. Injectable use is far less standardized and community figures for it disagree by roughly tenfold; the 500 mcg default here is the low end of that spread, chosen deliberately. Oral and subcutaneous amounts are not interchangeable and cannot be converted between routes, and no human study has compared them. All figures are community reference points, not a validated dose.
Where these numbers come from
No human dosing trial defines a dose for this compound by either route. The published animal work dosed mice 20 mg/kg subcutaneously three times daily for 11 days, which does not scale to the figures circulated online. Community oral and injectable numbers disagree by roughly tenfold — reference only.
- Neelakantan H et al., NNMT inhibitors reverse high fat diet-induced obesity in mice, Biochem Pharmacol 2018 (PubMed 29155147)
- Kraus et al., NNMT knockdown protects against diet-induced obesity, Nature 2014 (PubMed 24717514)
Reviewed August 2026
What it is
- A cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme implicated in fat-cell and liver energy metabolism.
- A synthetic quinolinium-based enzyme inhibitor — not a peptide, unlike most of this library.
- Studied preclinically by subcutaneous injection in mice — the key obesity study dosed 20 mg/kg three times daily for 11 days.
- Proposed to raise cellular NAD+ and SAM-pathway metabolites by blocking NNMT-mediated nicotinamide methylation.
How it is described to act
- 1
In the preclinical obesity work it was given by subcutaneous injection to mice and reported to be absorbed systemically; it is cell-permeable, and human use is predominantly oral.
- 2
Proposed to reach adipose and liver tissue, where NNMT is highly expressed.
- 3
Hypothesised to inhibit NNMT enzymatic activity, altering nicotinamide, NAD+ and polyamine metabolic flux — a pathway established mainly through genetic knockdown work.
- 4
In mouse models this was associated with reduced adiposity and improved metabolic markers; no evidence was located that this carries over to people.
What the research has looked at
The compound itself in obese mice
- Neelakantan et al. (Biochemical Pharmacology, 2018) reported that 5-Amino-1MQ given subcutaneously at 20 mg/kg three times daily for 11 days produced progressive body-weight loss and reduced white adipose mass in diet-induced obese mice, without a significant change in food intake.
- The same work reported the molecule is cell-permeable and selective, not inhibiting related SAM-dependent methyltransferases or NAD+ salvage pathway enzymes. This is mouse data — it establishes the compound acts on the target, not that it works or is safe in people.
Genetic foundation for the target
- Kraus et al. (Nature, 2014) reported that knocking down NNMT in adipose and liver tissue protected mice against diet-induced obesity, establishing NNMT as a metabolic drug target. This is knockdown evidence about the enzyme, not evidence about 5-Amino-1MQ in people.
Small-molecule inhibitor work
- Studies of NNMT-targeting small molecules have reported enzyme-inhibitory and anti-proliferative activity in cell models (2021), supporting proof of concept for pharmacological NNMT inhibition without demonstrating human obesity outcomes.
Strength of evidence: Preclinical evidence only
The evidence consists of rodent and cell-culture studies of NNMT inhibition; no peer-reviewed human clinical data were located, making this one of the least clinically validated entries in the library.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- No human safety or adverse-event data exist in the peer-reviewed literature located, because no formal human trials or regulatory review have taken place.
- The broader NNMT literature raises theoretical concerns about off-target inhibition in other tissues, including the liver; these have not been quantified for this compound in humans.
- Pregnancy and long-term organ-toxicity data are entirely unestablished, so safety claims in commercial listings are not supported by the sources reviewed.
References
- 1.Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice, Biochem Pharmacol (2018)
- 2.Kraus D et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity, Nature (2014)
- 3.van Haren MJ et al. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (2021)
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
5-Amino-1MQ questions people ask
How do you reconstitute 5-Amino-1MQ?
A common starting point for a 50 mg vial of 5-Amino-1MQ is 5 mL of bacteriostatic water, which gives 10 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of 5-Amino-1MQ is one dose?
At 10 mg per mL, that works out to about 5 units on a U-100 insulin syringe for a 500 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for 5-Amino-1MQ?
Published and community sources describe 150 mcg–5 mg (injectable, sources vary widely); 50–150 mg (oral), oral capsule (primary) / subcutaneous, every day, typically run 8 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should 5-Amino-1MQ be stored?
Lyophilized 5-Amino-1MQ vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.